Current and future use of hematopoietic growth factors in cancer medicine.
Mughal, Tariq I
Mughal, Tariq I
Citations
Altmetric:
Abstract
Myelosuppression, in particular neutropenia and anemia are serious complications of malignancy and its treatment. Neutropenia can make patients vulnerable to potentially life-threatening infection. It often results in dose reductions and delay of planned chemotherapy, which can have a significant detrimental effect on tumour response and survival. Anemia can be associated with a range of debilitating effects, which can severely impair patients' QOL. In addition, there is some evidence recognizing anemia as a poor prognostic indicator, associated with reduced treatment efficacy. Reduction in the duration and severity of neutropenia and anemia is possible by initiation of appropriate growth factors during the first and subsequent cycles of chemotherapy. New and improved growth factor support with agents such as pegfilgrastim and darbepoetin alfa has the potential to improve the management of chemotherapy-induced neutropenia and anemia further. Thrombopoietin is currently in clinical trials to assess its potential role in the treatment of thrombocytopenia in patients with cancer.
Authors
Description
Date
2004-09
Publisher
Collections
Keywords
Anaemia
Cancer
Haematopoietic Cell Growth Factors
Cancer
Haematopoietic Cell Growth Factors
Type
Article
Citation
Current and future use of hematopoietic growth factors in cancer medicine. 2004, 22 (3):121-34 Hematol Oncol